Medicenna Therapeutics' subsidiary Medicenna BioPharma has begun dosing patients in the Phase IIb trial of its MDNA55 to treat recurrent glioblastoma (rGB).

MDNA55 is a form of targeted immunotherapy being developed to remove tumour cells and adjacent immunosuppressive cells present in the tumour microenvironment that over-express interleukin-4 receptor (IL4R).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The multi-centre, single-arm, open-label Phase IIb trial will evaluate MDNA55 in around 43 adult patients who have progressed or recurred after prior therapy.  

A single intra-tumoural infusion of MDNA55 will be given through convection enhanced delivery (CED) technique, which is expected to result in minimal systemic side effects.

"We are pleased to be working with leading neuro-surgical centres in the US as we explore the benefits of MDNA55 for the treatment of rGB and other types of brain cancer."

Medicenna chairman and chief executive officer Dr Fahar Merchant said: "Dosing the first patient in this clinical trial is a significant milestone for the company as we look to build upon the promising results from earlier studies with MDNA55.

See Also:

"We are pleased to be working with leading neuro-surgical centres in the US as we explore the benefits of MDNA55 for the treatment of rGB and other types of brain cancer."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The primary endpoint of the trial is measure of overall response rate (ORR) using magnetic resonance imaging and the revised assessment in neuro-oncology (RANO) criteria.

The trial will also assess secondary outcomes such as progression-free survival, overall survival and exploratory predictors of outcome examined utilising IL4R expression in archived tumour biopsies.

The trial's enrolment will be conducted at up to ten sites in the US and is estimated to be completed by the end of this year, while the top-line data is expected to be available in the first half of next year.